Baseline predictors of placebo response in Exercise-Induced Bronchoconstriction (EIB): Pooled regression analysis from three studies of montelukast in EIB

Journal of Asthma

Volumn 47, Issue 8, 2010, Pages 935-941

  Philip, George ^a   Swern, Arlene S ^b   Smugar, Steven S ^a   Pearlman, David S ^c  

^a MERCK RESEARCH LABORATORIES   (United States)

^b CELGENE CORPORATION   (United States)

^c Respiratory Institute   (United States)

Author keywords

Asthma; Baseline; Demographic analysis; Exercise induced bronchospasm; Montelukast; Placebo response

Indexed keywords

MONTELUKAST; PLACEBO; ACETIC ACID DERIVATIVE; ANTIASTHMATIC AGENT; QUINOLINE DERIVATIVE;

ADULT; AGE; ARTICLE; ASTHMATIC STATE; CLINICAL EVALUATION; CONSULTATION; CORRELATION ANALYSIS; DEMOGRAPHY; DISEASE SEVERITY; EXERCISE INDUCED ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; NOCTURNAL ASTHMA; PLACEBO EFFECT; PREDICTIVE VALIDITY; REGRESSION ANALYSIS; SINGLE DRUG DOSE; ADOLESCENT; ASTHMA, EXERCISE-INDUCED; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; YOUNG ADULT;

ACETATES; ADOLESCENT; ADULT; ANTI-ASTHMATIC AGENTS; ASTHMA, EXERCISE-INDUCED; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PLACEBO EFFECT; QUINOLINES; YOUNG ADULT;

EID: 77957370212     PISSN: 02770903     EISSN: 15324303     Source Type: Journal    
DOI: 10.3109/02770903.2010.498541     Document Type: Article

References (40)

1. Beecher HK. The powerful placebo. J Am Med Assoc 1955; 159: 1602-1606.
2. Kaptchuk TJ, Kelley JM, Deykin A, Wayne PM, Lasagna LC, Epstein IO, Kirsch I, Wechsler ME. Do "placebo responders" exist? Contemp Clin Trials 2008; 29:587-595.
3. Ross SR, Buckalew LW. The placebo as an agent in behavioral manipulation: a review of problems, issues, and affected measures. Clin Psychol Rev 1983; 3:457-471.
4. Hrobjartsson A, Gotzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001; 344:1594-1602.
5. Hrobjartsson A, Gotzsche PC. Placebo interventions for all clinical conditions. Cochrane Database Syst Rev 2004; (3):CD003974.
6. Kienle GS, Kiene H. Placebo effect and placebo concept: a critical methodological and conceptual analysis of reports on the magnitude of the placebo effect. Altern Ther Health Med 1996; 2:39-54. (Pubitemid 126466083)
7. Krogsboll LT, Hrobjartsson A, Gotzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Med Res Methodol 2009; 9:1.
8. Luparello T, Lyons HA, Bleecker ER, McFadden ER Jr. Influences of suggestion on airway reactivity in asthmatic subjects. Psychosom Med 1968; 30:819-825.
9. Luparello TJ, Leist N, Lourie CH, Sweet P. The interaction of psychologic stimuli and pharmacologic agents on airway reactivity in asthmatic subjects. Psychosom Med 1970; 32:509-513.
10. Kemeny ME, Rosenwasser LJ, Panettieri RA, Rose RM, Berg-Smith SM, Kline JN. Placebo response in asthma: a robust and objective phenomenon. J Allergy Clin Immunol 2007; 119:1375-1381.
11. Godfrey S, Silverman M. Demonstration by placebo response in asthma by means of exercise testing. J Psychosom Res 1973; 17:293-297.
12. Boner AL, Vallone G, Peroni DG, Piacentini GL, Gaburro D. Efficacy and duration of action of placebo responses in the prevention of exercise-induced asthma in children. J Asthma 1988; 25:1-5.
13. Muittari A. Analysis of the placebo effect and spontaneous changes of airway obstruction in asthmatic patients. Ann Med Exp Biol Fenn 1968; 46:282-287.
14. Joyce DP, Jackevicius C, Chapman KR, McIvor RA, Kesten S. The placebo effect in asthma drug therapy trials: a meta-analysis. J Asthma 2000; 37:303-318.
15. Wilson BA, Evans JN. Standardization of work intensity for evaluation of exercise-induced bronchoconstriction. Eur J Appl Physiol Occup Physiol 1981; 47:289-294.
16. Knopfli BH, Bar-Or O, Araujo CG. Effect of ipratropium bromide on EIB in children depends on vagal activity. Med Sci Sports Exerc 2005; 37: 354-359.
17. Thio BJ, Slingerland GL, Nagelkerke AF, Roord JJ, Mulder PG, Dankert-Roelse JE. Effects of single-dose fluticasone on exercise-induced asthma in asthmatic children: a pilot study. Pediatr Pulmonol 2001; 32: 115-121.
18. Helenius IJ, Tikkanen HO, Haahtela T. Occurrence of exercise induced bronchospasm in elite runners: dependence on atopy and exposure to cold air and pollen. Br J Sports Med 1998; 32:125-129.
19. Anderson SD, Charlton B, Weiler JM, Nichols S, Spector SL, Pearlman DS. Comparison of mannitol and methacholine to predict exercise-induced bronchoconstriction and a clinical diagnosis of asthma. Respir Res 2009; 10:4.
20. Parsons JP, Mastronarde JG. Exercise-induced asthma. Curr Opin Pulm Med 2009; 15:25-28.
21. Godfrey S. Controversies in the pathogenesis of exercise-induced asthma. Eur J Respir Dis 1986; 68:81-88.
22. Pearlman DS, van Adelsberg J, Philip G, Tilles SA, Busse W, Hendeles L, Loeys T, Dass SB, Reiss TF. Onset and duration of protection against exercise-induced bronchoconstriction by a single oral dose of montelukast. Ann Allergy Asthma Immunol 2006; 97:98-104.
23. Philip G, Pearlman DS, Villaran C, Legrand C, Loeys T, Langdon RB, Reiss TF. Single-dose montelukast or salmeterol as protection against exercise-induced bronchoconstriction. Chest 2007; 132:875-883.
24. Philip G, Villaran C, Pearlman DS, Loeys T, Dass SB, Reiss TF. Protection against exercise-induced bronchoconstriction two hours after a single oral dose of montelukast. J Asthma 2007; 44:213-217.
25. Morton V, Torgerson DJ. Regression to the mean: treatment effect without the intervention. J Eval Clin Pract 2005; 11:59-65.
26. Leigh R, MacQueen G, Tougas G, Hargreave FE, Bienenstock J. Change in forced expiratory volume in 1 second after sham bronchoconstrictor in suggestible but not suggestion-resistant asthmatic subjects: a pilot study. Psychosom Med 2003; 65:791-795.
27. Center for Drug Evaluation and Research. Guidance for Industry. Exercise-Induced Bronchospasm (EIB)-Development of Drugs to Prevent EIB. Washington, DC: Food and Drug Administration, 2002.
28. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med 2000; 161:309-329.
29. Joos GF, O'Connor B, Anderson SD, Chung F, Cockcroft DW, Dahlen B, et al. Indirect airway challenges. Eur Respir J 2003; 21:1050-1068.
30. Bonini S, Brusasco V, Carlsen KH, Delgado L, Del Giacco SR, Haahtela T, Rasi G, van Cauwenberge PB. Diagnosis of asthma and permitted use of inhaled beta2-agonists in athletes. Allergy 2004; 59:33-36.
31. Helenius I, Lumme A, Haahtela T. Asthma, airway inflammation and treatment in elite athletes. Sports Med 2005; 35:565-574.
32. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seiden-berg BC, Knorr B. Montelukast once daily inhibits exercise-induced bron-choconstriction in 6- to 14-year-old children with asthma. J Pediatr 1998; 133:424-428.
33. Pearlman DS, Ostrom NK, Bronsky EA, Bonuccelli CM, Hanby LA. The leukotriene D4-receptor antagonist zafirlukast attenuates exercise-induced bronchoconstriction in children. J Pediatr 1999; 134:273-279.
34. Gill JS, Zezulka AV, Beevers DG, Davies P. Relation between initial blood pressure and its fall with treatment. Lancet 1985; 1:567-569.
35. Morton V, Torgerson DJ. Effect of regression to the mean on decision making in health care. BMJ 2003; 326:1083-1084.
36. Blance A, Tu YK, Baelum V, Gilthorpe MS. Statistical issues on the analysis of change in follow-up studies in dental research. Community Dent Oral Epidemiol 2007; 35:412-420.
37. Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, et al. The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol 2007; 119:73-80.
38. Bousquet J, Wenzel S, Holgate S, Lumry W, Freeman P, Fox H. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 2004; 125:1378-1386. (Pubitemid 38501353)
39. Bacharier LB, Guilbert TW, Zeiger RS, Strunk RC, Morgan WJ, Lemanske RF Jr, et al. Patient characteristics associated with improved outcomes with use of an inhaled corticosteroid in preschool children at risk for asthma. J Allergy Clin Immunol 2009; 123:1077-1082.
40. Zielen S, Christmann M, Kloska M, Dogan-Yildiz G, Lieb A, Rosewich M, Schubert R, Rose MA, Schulze J. Predicting short term response to anti-inflammatory therapy in young children with asthma. Curr Med Res Opin 2010; 26:483-492.